304 related articles for article (PubMed ID: 8282823)
21. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
22. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
Onoe Y; Miyaura C; Ito M; Ohta H; Nozawa S; Suda T
J Bone Miner Res; 2000 Mar; 15(3):541-9. PubMed ID: 10750569
[TBL] [Abstract][Full Text] [Related]
23. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
24. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.
Cui L; Wu T; Liu YY; Deng YF; Ai CM; Chen HQ
Acta Pharmacol Sin; 2004 May; 25(5):678-84. PubMed ID: 15132837
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
26. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
[TBL] [Abstract][Full Text] [Related]
27. In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator.
Arshad M; Sengupta S; Sharma S; Ghosh R; Sawlani V; Singh MM
J Steroid Biochem Mol Biol; 2004 Jun; 91(1-2):67-78. PubMed ID: 15261309
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
29. Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues.
Tasci A; Bilgili H; Altunay H; Gecit MR; Keskin D
Eur J Pharmacol; 2010 Feb; 627(1-3):354-61. PubMed ID: 19903467
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
31. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
[TBL] [Abstract][Full Text] [Related]
32. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
33. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
34. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
[TBL] [Abstract][Full Text] [Related]
35. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
36. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
37. Raloxifene preserves bone strength and bone mass in ovariectomized rats.
Turner CH; Sato M; Bryant HU
Endocrinology; 1994 Nov; 135(5):2001-5. PubMed ID: 7956922
[TBL] [Abstract][Full Text] [Related]
38. A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats.
Ammann P; Bourrin S; Brunner F; Meyer JM; Clément-Lacroix P; Baron R; Gaillard M; Rizzoli R
Bone; 2004 Jul; 35(1):153-61. PubMed ID: 15207751
[TBL] [Abstract][Full Text] [Related]
39. Effects of cod bone gelatin on bone metabolism and bone microarchitecture in ovariectomized rats.
Han X; Xu Y; Wang J; Pei X; Yang R; Li N; Li Y
Bone; 2009 May; 44(5):942-7. PubMed ID: 19124090
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats.
Westerlind KC; Gibson KJ; Malone P; Evans GL; Turner RT
J Bone Miner Res; 1998 Jun; 13(6):1023-31. PubMed ID: 9626634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
